Furthermore, meta-regression demonstrated that study region (P = .517), cancer type (P = .074), clinical stage (P = .080), sample size (P = .428), the proportion of patients with low NDRG2 expression (P = .294), and analysis method (P = .238) were not able to explain the source of heterogeneity. The gene discussed is NDRG2; the disease is cancer.